drugset / Trial / NCT02715882
Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer
RandomizedParallel-groupSingle-blindTreatment
Summary
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
Timeline
- Start
- 2015-11
- Primary completion
- 2017-02
- Completion
- 2017-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entolimod | Unknown | 0.35 ug/kg | Subcutaneous |
| Subject | Entolimod | Unknown | 0.45 ug/kg | Subcutaneous |